HOME >> MEDICINE >> NEWS
Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers

Orqis Medical Corp. today announced that the U.S. Food and Drug Administration has approved an expansion of the Cancion CRSTM clinical trial from eight to 40 medical centers nationwide, accelerating the trial's recruitment and enrollment efforts.

The Cancion CRS therapy is a percutaneous cardiac recovery system being studied for its ability to create a "rest-to-recovery" environment for congestive heart failure (CHF) patients. Enrollment in the Multicenter trial of the Orqis Medical CRS for the ENhanced Treatment of CHF, Unresponsive to Medical Therapy (MOMENTUM) trial began in September of this year.

"We've worked with the FDA to develop an effective protocol for the MOMENTUM trial and are gratified that we can now ramp up to a full complement of sites," said Marvin A. Konstam, M.D., Medical Director of Orqis Medical and Chief of Cardiology at Tufts-New England Medical Center in Boston. "This puts us yet another step closer to our goal of documenting the value that the Cancion therapy can bring to patients with heart failure."

Heart failure is the deterioration of the heart's ability to pump blood throughout the body and adequately perfuse the major organs. According to the AHA, some five million Americans have heart failure and an additional 550,000 are diagnosed annually. The single most expensive diagnosis in the U.S. health care system, acutely decompensated heart failure, represents 1 million primary and 2.5 million secondary hospital admissions annually.

About The Cancion CRS Therapy
A breakthrough discovery in hemodynamics -- the simple supplementation of blood flow specifically in the descending aorta -- led to the development of the Cancion CRS therapy, which centers on the novel use of a blood pump and proprietary peripheral access to the circulatory system.

The Cancion CRS increases blood flow in the descending aorta without t
'"/>

Contact: Kimberly Goolsby
kimberly@goolsbygroup.com
949-464-0187
Goolsby Group
10-Jan-2005


Page: 1 2

Related medicine news :

1. New data on Orqis Medicals Cancion CRS to be reported at ACC
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
10. Pfizers antifungal medicine VFEND receives FDA approval
11. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... ... 19, 2017 , ... The Semper Fi Fund, one of the nation’s highest-rated ... series of videos and a compelling documentary that provide unique insights and powerful advice ... part of its ongoing mission. , Each of the videos focuses on a specific ...
(Date:9/19/2017)... Montclair, NJ (PRWEB) , ... September 19, 2017 ... ... fall following the success of the annual PAINWeek National Conference. On October 7, ... will be an educational and exciting program providing busy clinicians and allied healthcare ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... board-certified veterinary oncologist, has agreed to serve as strategic adviser to the ... Tripp is founder of the Bridge Animal Referral Center (BARC) in Edmonds, ...
(Date:9/19/2017)... Reno, Nev. (PRWEB) , ... September 19, 2017 ... ... 20 students across the country with the Davidson Fellows Scholarship on September 27 ... awards for projects in Science, Technology, Engineering, Mathematics, Literature and Music. , “I ...
(Date:9/19/2017)... ... September 19, 2017 , ... With Netmail Hadron, ... the United States, can easily manage all of their data, apply policies on ... platforms simultaneously. “As a construction company,” says Ryan Sinnwell, the Infrastructure Manager at ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Del. , Sept. 6, 2017 NeuroRx, a ... Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast ... its sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 ... in a pivotal trial of this sequential therapy targeting patients ... depression. 1 ...
(Date:9/5/2017)... 5, 2017 Sapheneia and Scannerside received FDA ... DoseCheck is a third-party Vendor neutral CT product that ... allows compliance with current MITA standards. ... DoseCheck solution is specifically designed to provide CT operators, ... radiation doses over a predefined threshold. Scannerside Dose Check ...
(Date:9/5/2017)... 2017  Getinge, a leading global provider of ... donation program -- "Color for the Kids!" -- ... research by The Children,s Heart Foundation. Pediatric patients ... are encouraged to download a coloring picture at ... to the gallery on the website. For each ...
Breaking Medicine Technology:
Cached News: